Endogenous Follistatin-like 1 guarantees the immunomodulatory properties of mesenchymal stem cells during liver fibrotic therapy

Endogenous Follistatin-like 1 guarantees the immunomodulatory properties of mesenchymal stem cells during liver fibrotic therapy

Abstract Background Mesenchymal stem cell (MSC) therapy has been shown to be a promising option for liver fibrosis treatment. However, critical factors affecting the efficacy of MSC therapy for liver fibrosis remain unknown. Follistatin-like 1 (FSTL1), a TGF-β-induced matricellular protein, is docum...

Full description

Bibliographic Details
Main Authors: Xiaohong Zheng, Xia Zhou, Gang Ma, Jiahao Yu, Miao Zhang, Chunmei Yang, Yinan Hu, Shuoyi Ma, Zheyi Han, Wen Ning, Boquan Jin, Xinmin Zhou, Jingbo Wang, Ying Han
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Stem Cell Research & Therapy
Subjects:
FSTL1
Mesenchymal stem cells
Liver cirrhosis
Cell therapy
Immunosuppressive
Online Access:https://doi.org/10.1186/s13287-022-03042-4

Internet

https://doi.org/10.1186/s13287-022-03042-4

Similar Items